Altimmune is a late clinical-stage biopharmaceutical company focused on serious liver and metabolic disease. Its lead candidate, pemvidutide, is an investigational peptide with balanced glucagon and GLP-1 dual receptor agonist activity. Development targets metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder and alcohol-associated liver disease.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -19.6 | — |
| Q2 2025 | 0 | — | -22.1 | — |
| Q3 2025 | 0 | — | -19 | — |
| Q4 2025 | 0 | — | -27.4 | — |
| Q1 2026 | 0 | -100% | -22.6 | — |
| Q2 2026 | 0 | -100% | -22.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: MapLight Therapeutics, Inc. (MPLT), Bank of Marin Bancorp (BMRC), TAT Technologies Ltd. (TATT), Gladstone Capital Corporation (GLAD), Monro, Inc. (MNRO), Autolus Therapeutics plc (AUTL)